Back in April 2024, I assigned Day One Biopharmaceuticals, Inc. (DAWN) stock a "Hold" rating in a note for the Seeking Alpha, covering the news that its lead asset tovorafenib had been awarded an ...
The last time I spoke about Day One Biopharmaceuticals, Inc. (DAWN), it was in a Seeking Alpha article entitled "Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch." With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback